BioXcel Therapeutics (Nasdaq: BTAI)

Today, the FDA has accepted our sNDA for IGALMI® for at-home use in treating acute agitation associated with bipolar disorders or schizophrenia. If approved, IGALMI would be the first FDA-approved outpatient option. PDUFA date: Nov 14, 2026. More: bit.ly/41m7r9U #FDA#BTI

We are excited to have received a positive recommendation from an independent Data Safety Monitoring Board to continue, as planned, our SERENITY At-Home trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Learn more. bit.ly/4kfwraI

It's estimated that more than 20 million people live with schizophrenia worldwide. Learn the facts about agitation associated with schizophrenia and show your support for World Schizophrenia Awareness Day 2025 on May 24. bit.ly/3kV6Erl

This #MentalAwarenessMonth,we’re reminding you about the 988 hotline that provides access to mental health support to everyone in the U.S. bit.ly/3Mmtrtr

We are pleased to report our first quarter 2025 financial results and announce that enrollment is complete in our SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. bit.ly/4j0th9s

This #MentalHealthMonth, we’re encouraging you to learn the facts about agitation, which is relatively common in adults with schizophrenia or bipolar disorders. Recognizing agitation earlier can help those affected manage symptoms before they escalate. bit.ly/3kV6Erl

We stand with those affected by mental illness to raise awareness and let them know they are not alone. Find resources to help people experiencing mental illness. bit.ly/4jx6frB

While there is no consensus on the cause of agitation associated with bipolar disorder or schizophrenia, neurochemical imbalances and anatomical changes in the brain are believed to contribute to its development and clinical manifestations. Learn more. bit.ly/423hL7U

Expert consensus best practice guidelines recommend treating agitation related to bipolar disorder or schizophrenia with a combination of behavioral calming techniques, verbal de-escalation & medications voluntarily accepted by patients without coercion. bit.ly/423hL7U

Managing agitation associated with bipolar disorder or schizophrenia allows clinicians to talk to patients and determine the cause of symptoms. Learn more about cooperative de-escalation approaches. bit.ly/423hL7U

Research has shown that the foremost goal of treating agitation associated with bipolar disorder or schizophrenia with medication is to prevent harm to clinicians, patients, and self. Learn more about agitation treatment guidelines. bit.ly/423hL7U

We released our Q4 and full year 2024 financial results today! Learn more. bit.ly/3QQGciw

BioXcel Therapeutics strengthens cash position to advance SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Learn more. bit.ly/3XHrrlI

We are pleased with the progress of our SERENITY At-Home trial for the acute treatment of agitation associated with bipolar disorders or schizophrenia. Learn more. bit.ly/41wD5kx

We are pleased to share important clinical and business updates at BioXcel Therapeutics! Learn more. bit.ly/3CN7nHp

Thanks to Boehringer Ingelheim and BioCT for sponsoring the recent #AISummit. We are pleased that our VP of AI Drug Discovery, Friso Postma, joined a distinguished panel in sharing important insights about the impact of AI on pharma R&D.

Proud to announce that Friso Postma, our VP of AI Drug Discovery, will be speaking on a panel at Boehringer Ingelheim and BioCT’s #AISummit to discuss innovative applications of AI across research and development. Join us! #AI" target="_blank" rel="nofollow noopener">lu.ma/oijbjl9r#AI #ResearchandDevelopment

We have just announced our Q3 2024 earnings. Learn more. bit.ly/3YQUaVj

We are pleased to have advanced our pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia. Learn more. bit.ly/3AskPzB

We'll be reporting our third quarter 2024 financial results on November 14, 2024. Learn more. bit.ly/4fg5WQ0